News Updates

More Articles Back to Article

Avenue Therapeutics, Annji enter licensing deal for SBMA

Taiwan-based AnnJi Pharmaceutical has entered a licensing deal with Avenue Therapeutics to develop and commercialize AJ201 treatment for spinal and bulbar muscular atrophy, also known as Kennedy's disease. Under the licensing deal, AnnJi will receive an upfront payment of $3 million and is eligible for unspecified future milestone payments. BioSpectrum Asia (3/14)

Read full article now.

Articles are only one benefit of being a DIA member. Learn more and join today so you don’t miss another article!